← Alle mensen

JM

Joshua M Bauml

6 publicaties

PubMed → Google Scholar →

Publicaties op Oncologisch.com

Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Gevorderd NSCLC: A Gerandomiseerde, Double-Blind, E...

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-11

Totale overleving with Amivantamab-Lazertinib in EGFR-Mutated Gevorderd NSCLC.

The New England journal of medicine · 30 oktober 2025

Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Gevorderd NSCLC: The COC...

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2025-10

Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-smal...

European journal of cancer (Oxford, England : 1990) · 9 september 2025

Amivantamab plus lazertinib als eerstelijns bij EGFR-gemuteerd NSCLC: MARIPOSA fase III definitief

The New England journal of medicine · 24 oktober 2024

Subcutaan versus IV amivantamab plus lazertinib bij EGFR-gemuteerd NSCLC: PALOMA-3

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 20 oktober 2024